Loading patent…
OwnerUwe MASKOS, Sylvia LOMBARDO +3inventors
InventorsUwe MASKOS, Sylvia LOMBARDO, Julie CATTEAU, Morgane BESSON, Fani KOUKOULI
Estimating the term…
The invention provides methods of reducing development of mild cognitive impairment and/or learning disorders and/or memory disorders in a subject suspected to have or suffering from Alzheimer's disease (AD). In some embodiments, the methods comprise administering a therapeutically effective amount of a beta-2 nicotinic acetylcholine receptor (n AChR) antagonist and/or beta-2 nAChRnegative allosteric modulator (NAM) to the subject over a therapeutic dosing period to thereby reduce the rate of development of mild cognitive impairment and/or learning disorders and/or memory disorders in the subject over the therapeutic dosing period.
A method of preventing Alzheimer's disease (AD), treating AD or reducing development of mild cognitive impairment and/or learning disorders and/or memory disorders in a subject suspected to have or suffering from AD, comprising administering a therapeutically effective amount of a beta-2 nicotinic acetylcholine receptor (nAChR) antagonist and/or beta-2 nAChR negative allosteric modulator (NAM) to the subject.
16-25. (canceled)
A method of preventing or treating Alzheimer's disease (AD) in a subject suspected to have or suffering from AD, or for reducing development of mild cognitive impairment and/or learning disorders and/or memory disorders in a subject suspected to have or suffering from AD, said method comprising administering simultaneously, separately or in a staggered manner a therapeutically effective amount of:
Dependencies are inferred from the claim text.